Akers Biosciences to Present at 'Pioneers 2016' Investor Conference
(firmenpresse) - THOROFARE, NJ -- (Marketwired) -- 05/04/16 -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR), (the "Company"), a developer of rapid health information technologies, is presenting at Joseph Gunnar & Co., LLC's 'Pioneers 2016' conference in New York on May 5, 2016.
Co-founder and Chief Scientific Director, Raymond F. Akers, Jr. PhD, will give a presentation on the Company to institutional and accredited investors.
Akers Biosciences develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be found at . Follow us on Twitter .
Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.
Raymond F. Akers, Jr. PhD
Co-founder and Chief Scientific Director
Tel. +1 856 848 8698
)
Chris Schreiber
Tel. +1 917 445 6207
Email:
Ben Simons / Fiona Henson
Tel. +44 (0)20 7830 9700
Email:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.05.2016 - 18:00 Uhr
Sprache: Deutsch
News-ID 468761
Anzahl Zeichen: 0
contact information:
Town:
THOROFARE, NJ
Kategorie:
Venture Capital
Diese Pressemitteilung wurde bisher 333 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Akers Biosciences to Present at 'Pioneers 2016' Investor Conference"
steht unter der journalistisch-redaktionellen Verantwortung von
Akers Biosciences, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
